Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, acquired 2022)
COLL · Nasdaq · United States
Share price · COLL
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when COLL's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 5 Nov 2026+6.3%
- 13 Aug 2026+9.5%
- 10 Aug 2026-7.7%
Nothing announced by COLL that day or the session before.
- 6 Aug 2026-18.6%
- 15 Jul 2026+4.9%
Nothing announced by COLL that day or the session before.
- 7 May 2026+7.7%
- 16 Apr 2026-5.4%
Nothing announced by COLL that day or the session before.
- 9 Apr 2026+5.4%
Nothing announced by COLL that day or the session before.
- 19 Mar 2026+4.3%
- 27 Feb 2026-5.8%
Share of unusual movement by asset
For each asset, the share of COLL's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Tapentadolevents and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 45% |
| Sessions with no dated event | — | 55% |
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | Opioid receptors (mu-opioid receptor partial agonist, kappa-opioid receptor antagonist)Small molecule | Chronic Pain | |
| Approved | Opioid receptors (mu-opioid receptor)Small molecule | Chronic Pain | |
| Approved | Mu-opioid receptor and norepinephrine transporter (NET)Small molecule | Diabetic Peripheral Neuropathic PainNeuropathic Pain Diabetic Peripheral Neuropathy, Peripheral Neuropathic Pain |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (21)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $216M | — | $166M+ $0 short-term inv. | —$87M operating cash flow | report ↗ |
View 20 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $200M | — | $150M+ $0 short-term inv. | $15M$71M operating cash flow | report ↗ |
| 2026-Q1 | $194M | — | $290M+ $153M short-term inv. | —$57M operating cash flow | report ↗ |
| 2025-Q4 | $205M | — | $252M+ $155M short-term inv. | —$123M operating cash flow | report ↗ |
| 2025-Q3 | $209M | — | $171M+ $136M short-term inv. | —$78M operating cash flow | report ↗ |
| 2025-Q2 | $188M | — | $138M+ $105M short-term inv. | —$72M operating cash flow | report ↗ |
| 2025-Q1 | $178M | — | $117M+ $102M short-term inv. | —$55M operating cash flow | report ↗ |
| 2024-Q4 | $182M | — | $97M+ $92M short-term inv. | —$85M operating cash flow | report ↗ |
| 2024-Q3 | $159M | — | $65M+ $81M short-term inv. | —-$9.0M operating cash flow | report ↗ |
| 2024-Q2 | $145M | — | $174M+ $99M short-term inv. | —$67M operating cash flow | report ↗ |
| 2024-Q1 | $145M | — | $230M+ $89M short-term inv. | —$62M operating cash flow | report ↗ |
| 2023-Q4 | $150M | — | $240M+ $72M short-term inv. | —$73M operating cash flow | report ↗ |
| 2023-Q3 | $137M | — | $260M+ $46M short-term inv. | —$74M operating cash flow | report ↗ |
| 2023-Q2 | $136M | — | $285M+ $42M short-term inv. | —$100M operating cash flow | report ↗ |
| 2023-Q1 | $145M | — | $272M | $17M$28M operating cash flow | report ↗ |
| 2022-Q4 | $130M | — | $176M+ $0 short-term inv. | $7.2M$66M operating cash flow | report ↗ |
| 2022-Q3 | $127M | — | $137M | —$43M operating cash flow | report ↗ |
| 2022-Q2 | $124M | $0 | $125M | $5.2M$40M operating cash flow | report ↗ |
| 2022-Q1 | $84M | $4.0M | $109M | $13M-$25M operating cash flow | report ↗ |
| 2021-Q4 | $27M | $1.6M | $189M | $25M$36M operating cash flow | report ↗ |
| 2021-Q3 | $79M | $1.4M | $196M | —$17M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $781M | — | $252M+ $155M short-term inv. | —$329M operating cash flow | report ↗ |
Collegium reported full-year 2025 product revenue of $780.57M, up 23.6% YoY, with fourth-quarter product revenue of $205.4M, up 13% YoY. R&D spend was not disclosed. Cash and equivalents were $252.16M, while cash, cash equivalents, and marketable securities were $386.7M at year-end. Full-year net income was $62.87M, with GAAP diluted EPS of $1.73.
Management reaffirmed 2026 guidance for product revenues of $805–825M, Jornay PM net revenue of $190–200M, and adjusted EBITDA of $455–475M. During 2025, the company presented Jornay PM data at four scientific congresses and completed four real-world evidence studies, and presented pain-portfolio data at three congresses with three real-world studies. In January, it announced supply and quality agreements with Hikma for authorized generics of Nucynta and Nucynta ER, with the Nucynta AG recently launched and Nucynta ER expected in Q1 2026. In December, it closed a $980M credit facility used partly to repay the remaining $581M of its prior term loan.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $631M | $0 | $97M+ $92M short-term inv. | —$205M operating cash flow | report ↗ |
| 2023-FY | $567M | $0 | $240M+ $72M short-term inv. | —$275M operating cash flow | report ↗ |
| 2022-FY | $464M | $4.0M | $176M+ $0 short-term inv. | $6.3M$124M operating cash flow | report ↗ |
| 2021-FY | $277M | $9.4M | $189M | —$104M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 11 sales ($4.4M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-12 | Karnani Vikram · director, President and CEO | Tax withholding | 11,737 | $24.95 | $293K | Form 4 |
| 2026-06-08 | SANTINI GINO · director | Option exercise | 8,700 | $16.49 | $143K | Form 4 |
| 2026-06-08 | SANTINI GINO · director | Option exercise (derivative) | 8,700 | — | — | Form 4 |
| 2026-05-18 | Freund John Gordon · director | Open-market sale | 20 | $34.05 | $681 | Form 4 |
| 2026-05-15 | Freund John Gordon · director | Option exercise | 8,700 | $16.49 | $143K | Form 4 |
| 2026-05-15 | Freund John Gordon · director | Open-market sale | 4,127 | $34.54 | $143K | Form 4 |
| 2026-05-15 | Freund John Gordon · director | Option exercise (derivative) | 8,700 | — | — | Form 4 |
| 2026-05-14 | SANTINI GINO · director | Award / grant | 8,741 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 265 reporting institutions held 37.7M shares ($1.2B, 121.3% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 5,134,027 | $169.8M |
| 2 | JANUS HENDERSON GROUP PLC | 1,825,651 | $60.4M |
| 3 | Invesco Ltd. | 1,591,909 | $52.6M |
| 4 | FULLER & THALER ASSET MANAGEMENT, INC. | 1,499,584 | $49.6M |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 1,469,449 | $48.6M |
| 6 | STATE STREET CORP | 1,424,544 | $47.1M |
| 7 | EVENTIDE ASSET MANAGEMENT, LLC | 1,424,282 | $47.1M |
| 8 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 1,365,932 | $45.2M |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 1,333,992 | $44.1M |
| 10 | PRINCIPAL FINANCIAL GROUP INC | 1,295,028 | $42.8M |
| 11 | Rubric Capital Management LP | 1,279,611 | $42.3M |
| 12 | DIMENSIONAL FUND ADVISORS LP | 833,192 | $27.6M |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 819,440 | $27.1M |
| 14 | MARSHALL WACE, LLP | 748,812 | $24.8M |
| 15 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 703,528 | $23.3M |